These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22157200)

  • 1. Is sugammadex economically viable for routine use.
    Fuchs-Buder T; Meistelman C; Schreiber JU
    Curr Opin Anaesthesiol; 2012 Apr; 25(2):217-20. PubMed ID: 22157200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment.
    Chambers D; Paulden M; Paton F; Heirs M; Duffy S; Craig D; Hunter J; Wilson J; Sculpher M; Woolacott N
    Health Technol Assess; 2010 Jul; 14(39):1-211. PubMed ID: 20688009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O; White PF; Tufanogullari B; Klein K
    Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment.
    Chambers D; Paulden M; Paton F; Heirs M; Duffy S; Hunter JM; Sculpher M; Woolacott N
    Br J Anaesth; 2010 Nov; 105(5):568-75. PubMed ID: 20937718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia?
    Meistelman C; Donati F
    Curr Opin Anaesthesiol; 2016 Aug; 29(4):462-7. PubMed ID: 27168088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
    Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
    Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
    White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
    Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.
    Lee C; Jahr JS; Candiotti KA; Warriner B; Zornow MH; Naguib M
    Anesthesiology; 2009 May; 110(5):1020-5. PubMed ID: 19387176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
    Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can sugammadex save a patient in a simulated 'cannot intubate, cannot ventilate' situation?
    Bisschops MM; Holleman C; Huitink JM
    Anaesthesia; 2010 Sep; 65(9):936-41. PubMed ID: 21198485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex.
    Ploeger BA; Smeets J; Strougo A; Drenth HJ; Ruigt G; Houwing N; Danhof M
    Anesthesiology; 2009 Jan; 110(1):95-105. PubMed ID: 19104176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C; Bergner UA; Pühringer FK
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of sugammadex.
    Caldwell JE; Miller RD
    Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    Blobner M; Eriksson LI; Scholz J; Motsch J; Della Rocca G; Prins ME
    Eur J Anaesthesiol; 2010 Oct; 27(10):874-81. PubMed ID: 20683334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sugammadex: the first selective binding reversal agent for neuromuscular block.
    Kovac AL
    J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sugammadex: a novel neuromuscular blocker binding agent.
    Fields AM; Vadivelu N
    Curr Opin Anaesthesiol; 2007 Aug; 20(4):307-10. PubMed ID: 17620836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.